Traws Pharma, Inc. Common Stock

TRAWNASDAQ • USD
ThemeBiotech - Drug Development›Infectious Disease & Vaccines
1.37 USD
↘ 0.11 (7.43%)AT CLOSE (11:59 AM EDT)
1.40
↗ 0.03 (2.19%)
POST MARKET (AS OF 07:54 PM EDT)
Post Market
AS OF 07:54 PM EDT
1.40
↗ 0.03 (2.19%)
🔴Market: CLOSED
Open?$1.45
High?$1.46
Low?$1.33
Prev. Close?$1.48
Volume?354.5K
Avg. Volume?4.4M
VWAP?$1.40
Rel. Volume?0.08x
Bid / Ask
Bid?$1.38 × 200
Ask?$1.43 × 600
Spread?$0.05
Midpoint?$1.40
Valuation & Ratios
Market Cap?20.8M
Shares Out?15.2M
Float?5.0M
Float %?62.1%
P/E Ratio?N/A
P/B Ratio?-3.91
EPS?-$0.97
Dividend?0.00%
Ex-Dividend?N/A

Traws Pharma, Inc. Common Stock (TRAW) is currently trading at $1.37. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (277.7%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation front, TRAW trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Themes
Biotech - Drug Development›Infectious Disease & Vaccines
Employees
7
Market Cap
20.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.trawspharma.com
Listed
2013-07-25
Address
12 PENNS TRAIL
NEWTOWN, PA 18940
Phone: 267-759-3680
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
23
Short Sent.?
25
Piotroski F-Score?0/9Weak
Altman Z-Score?-118.86Distress
Confidence?57%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?33.68%Squeeze Risk
Short Interest?1.7M
Days to Cover?1.0
Free Float5.0M
Avg Daily Volume10.8M
Settlement Date2026-05-15
Financial Health
Current Ratio?0.43Weak
Quick Ratio?0.43Weak
Cash Ratio?0.24Low
Debt/Equity?-0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
S&P
97
-3.91CHEAP▾
P/S?
Peers
100
S&P
15
7.59HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.9CHEAP▾
EV/Sales?
Peers
100
S&P
24
6.45HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
277.7%STRONG▾
ROA?
S&P
3
-180.9%WEAK▾
Cash Flow & Enterprise
FCF?$-17909000
Enterprise Value?$17.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist